Organism: Homo sapiens
Gene: 1146_at
Selected probe(set): 203547_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1146_at (203547_at) across 6540 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):-3.3724422
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (novicida)
	Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):-3.3304825
Number of Samples:7 / 12

Experimental	IL-4; GM-CSF study 1 (intermediate)
	Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control	untreated monocyte sample
	Freshly isolated human monocytes from healthy donors.

Relative Expression (log2-ratio):-3.2554884
Number of Samples:3 / 3

Experimental	VTX-2337 study 1
	Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control	3M-055 study 1
	Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM 3M-055 drug, which represents a TLR7 (Toll-like receptor 7) agonist.

Relative Expression (log2-ratio):-3.0776062
Number of Samples:3 / 3

Experimental	VTX-2337 study 1
	Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities.
Control	untreated monocyte sample
	Peripheral blood monocytes isolated from healthy donors.

Relative Expression (log2-ratio):-2.969121
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (tularensis Schu S4)
	Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):-2.9423084
Number of Samples:17 / 22

Experimental	septic shock study 3 (D1; non-survivor)
	Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine. The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control	normal blood sample
	Blood samples from healthy subjects.

Relative Expression (log2-ratio):-2.9413433
Number of Samples:2 / 2

Experimental	expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control	expO ovary cancer study 1 (dysgerminoma; metastatic)
	Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary.

Relative Expression (log2-ratio):-2.9360218
Number of Samples:5 / 5

Experimental	monocyte activation study 1 (NOD2L; 24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and activated for 24 hours with 1 ug/ml muramyl dipeptide (nucleotide-binding oligomerization domain-containing protein 2 ligand, NOD2L). This type of activation is via nucleotide-binding oligomerization domain-containing protein 2 (NOD2) induces preferentially monocyte differentiation into dendritic cells.
Control	untreated monocyte sample (24h)
	Monocytes were isolated from five healthy donors, cultured in RPMI with 10% vitamin D–sufficient (100 nM) human serum and collected after 24 hours for RNA isolation.

Relative Expression (log2-ratio):-2.859558
Number of Samples:2 / 2

Experimental	IFN-g; LPS study 1
	Monocytes LPS/IFN-g activated for 30h.
Control	normal resting monocyte sample
	Monocytes resting for 30h.

Relative Expression (log2-ratio):-2.6488924
Number of Samples:8 / 22

Experimental	septic shock study 3 (D2; non-survivor)
	Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine. The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control	normal blood sample
	Blood samples from healthy subjects.